Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary ...

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...

Xavier Leleu, MD, PhD, is the head of the Department of Haematology and the Myeloma Clinic at Hôpital La Mileterie, in Poitiers, France.

The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory multiple ...

Patients with relapsed/refractory (R/R) multiple myeloma and lower socioeconomic status reported significantly worse quality of life and a higher burden of symptoms, according to Francesco Sparano, ...

The potential therapy for idiopathic pulmonary fibrosis is notable because not only was the small molecule discovered by ...

For children with severe Crohn disease, upadacitinib offers an effective induction therapy, but its benefits must be ...

Our knowledge of the effects of space and low gravity on blood cells, clotting, and anemia continues to expand, but further ...

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed ...

A new analysis of obesity guidelines suggests more evidence is needed to develop stronger guidelines for the transition ...